KemPharm (NASDAQ: KMPH) shares are surging premarket on Tuesday after the company announced that the US Food and Drug Administration has approved the New Drug Application for AZSTARYS.
AZSTARYS is a once-daily product for treating attention-deficit hyperactivity disorder or ADHD in patients age 6 years or older.
Corium Inc, a portfolio company of Gurnet Point Capital, will lead the commercialisation of the drug and expect it to be commercially available in the US as early as the second half of 2021.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
As a result of the approval, KemPharm has earned a regulatory milestones payment as provided under the licence agreement with Gurnet and is working with the company to evaluate the related provisions and amounts.
Under the agreement, they may be eligible for up to $468 million in regulatory sales and milestone payments as well as tiered royalty payments.
“The FDA approval of the AZSTARYS NDA is a transformational event for KemPharm and, we believe, an important advancement in the treatment of ADHD,” said Travis C Mickle, President and CEO of KemPharm.
The company shares are trading 95.12% higher premarket at $18.40.
